The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.

STAT6 degradation is expected to provide a clinical benefit for patients with Type 2 inflammatory diseases, including asthma.

The contaminated products, distributed exclusively to physician offices, may increase the risk for infection, skin irritation, or delayed wound healing.

HealthDay News — Influenza vaccination may offer cardiovascular protection even when it does not prevent infection, according to a study published online April 2 in Eurosurveillance.

HealthDay News — For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to ...

Despite the initiation of a phase 3 confirmatory trial, the FDA remains unsatisfied with the interpretability of phase 2 data for Replimune’s oncolytic immunotherapy.

The report, from the US Centers for Disease Control and Prevention (CDC), found that COVID vaccines reduced emergency room ...

Access to the pill has become a major issue in the wake of the 2022 US Supreme Court decision that allowed states to ban abortion. HealthDay News — US District Judge David Joseph turned down Louisiana ...

HealthDay News — Growing demand for estrogen patches to relieve menopause symptoms has led to shortages, leaving women searching multiple pharmacies or switching medications. Experts say the shortages ...

Minoxidil is a medication used to treat hair loss, but it can be harmful if ingested. As required by the Poison Prevention Packaging Act, products like this must be sold in child-resistant packaging.

Cancer SIFs associated with increased risk for extrapulmonary cancer diagnosis in the year following an LDCT lung cancer screening exam.